InvestSMART

Neurizon Therapeutics Limited (ASX: NUZ) - Announcements

- Current share price for NUZ : $0.075

ASX company news and announcements for Neurizon Therapeutics Limited (NUZ) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Neurizon Therapeutics Limited (NUZ) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Neurizon Therapeutics Limited (NUZ), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Neurizon Therapeutics Limited (NUZ)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$59 Appendix 4C & Quarterly Update 29 Oct 2025 9:42AM $0.125 $0.075 fallen by 40%
$59 Notice of Annual General Meeting/Proxy Form 23 Oct 2025 9:15AM $0.130 $0.075 fallen by 42.31%
$59 Australian Patent Granted for NUZ-001 21 Oct 2025 9:09AM $0.135 $0.075 fallen by 44.44%
$59 Quarterly Shareholder Update Webinar - Q1 FY2026 20 Oct 2025 4:17PM $0.135 $0.075 fallen by 44.44%
$59 Neurizon to Present Poster Data at 2025 NEALS Annual Meeting 10 Oct 2025 8:41AM $0.140 $0.075 fallen by 46.43%
$59 Proposed issue of securities - NUZ 8 Oct 2025 9:35AM $0.140 $0.075 fallen by 46.43%
$59 Neurizon Commences Trading on OTCQB Venture Market 8 Oct 2025 9:30AM $0.140 $0.075 fallen by 46.43%
$59 FDA Lifts Clinical Hold on NUZ-001 6 Oct 2025 8:55AM $0.145 $0.075 fallen by 48.28%
$59 Notification regarding unquoted securities - NUZ 1 Oct 2025 5:44PM $0.125 $0.075 fallen by 40%
$59 Section 708A Cleansing Statement 24 Sep 2025 9:32AM $0.145 $0.075 fallen by 48.28%
$59 Application for quotation of securities - NUZ 23 Sep 2025 11:24AM $0.145 $0.075 fallen by 48.28%
$59 R&D Tax Incentive Advance & Overseas Finding Approval 18 Sep 2025 9:25AM $0.140 $0.075 fallen by 46.43%
$59 Proposed issue of securities - NUZ 18 Sep 2025 9:25AM $0.140 $0.075 fallen by 46.43%
$59 Neurizon Raises $5m via Institutional Placement 18 Sep 2025 9:25AM $0.140 $0.075 fallen by 46.43%
$59 Trading Halt 16 Sep 2025 9:29AM $0.140 $0.075 fallen by 46.43%
$59 Change of AGM Date 1 Sep 2025 6:32PM $0.155 $0.075 fallen by 51.61%
$59 Neurizon to present Q4 updates to Shareholders 26 Aug 2025 10:47AM $0.155 $0.075 fallen by 51.61%
$59 Appendix 4G and Corporate Governance Statement 26 Aug 2025 9:41AM $0.150 $0.075 fallen by 50%
$59 Appendix 4E and 2025 Annual Report 26 Aug 2025 9:34AM $0.150 $0.075 fallen by 50%
$59 Notice of Shareholder Update Webinar 20 Aug 2025 4:14PM $0.160 $0.075 fallen by 53.13%
$59 NUZ-001 Shows Long-Term Safety and Efficacy Signals in OLE 20 Aug 2025 9:32AM $0.155 $0.075 fallen by 51.61%
$59 FDA Review Timeline Extended for NUZ-001 IND Clinical Hold 15 Aug 2025 9:54AM $0.170 $0.075 fallen by 55.88%
$59 Neurizon Commences Manufacture of First Registration Batch 12 Aug 2025 9:30AM $0.160 $0.075 fallen by 53.13%
$59 AGM Date & Director Nominations Closing Date for AGM 5 Aug 2025 9:03AM $0.160 $0.075 fallen by 53.13%
$59 Appendix 4C & Quarterly Update 30 Jul 2025 9:14AM $0.170 $0.075 fallen by 55.88%

101 - 125 of 185 results

Page 5 of 8

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.